| 摘要 |
Described herein are compositions, kits and methods for treating and preventing obesity and overweight, as well as treating and preventing hyperglycemia, in a subject (e.g., a human), based on the discoveries that reduced expression of miR-205 may be a cause of obesity, and that miR-411 regulates gluconeogenic genes by targeting transcription factors, respectively. The compositions, kits and methods for treating and preventing obesity and overweight involve increasing expression of one or more microRNAs (e.g., miR-205) involved in adipogenesis, and provide a new therapy for treating patients that have eating disorders and/or are predisposed to obesity, and that are obese or overweight. The compositions, kits and methods described herein for treating and preventing hyperglycemia involve increasing expression of miR-411 and provide a new therapy for treating hyperglycemia associated with, for example, type 2 diabetes. |
| 主权项 |
1. A method of treating or preventing obesity or overweight in a subject, the method comprising administering to the subject a composition comprising at least one agent that increases expression of at least one microRNA (miR) selected from the group consisting of: miR-200a, miR-200b, miR-200c, miR-143, and miR-205 in a therapeutically effective amount for treating or preventing obesity or overweight in the subject, and a pharmaceutically acceptable carrier, wherein administration of the composition reduces adiposity levels and adipose production in the subject. |
